A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). The new paper by Punnoose et al. (which is available as a full text article), along with […]![]()
